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SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indolinone; semaxanib) is a small molecule inhibitor of the vascular
endothelial growth factor receptor (VEGFR2). A Phase I dose escalation study was performed. Dynamic contrast-enhanced
magnetic resonance imaging (DCE-MRI) was used as a pharmacodynamic assessment tool. In all, 27 patients were recruited. SU5416
was administered twice weekly by fixed rate intravenous infusion. Patients were treated in sequential cohorts of three patients at 48,
65, 85 110 and 145mgm
 2. A further dose level of 190mgm
 2 after a 2-week lead in period at a lower dose was completed;
thereafter, the cohort at 145mgm
 2 was expanded. SU5416 showed linear pharmacokinetics to 145mgm
 2 with a large volume of
distribution and rapid clearance. A significant degree of interpatient variability was seen. SU5416 was well tolerated, by definition a
maximum-tolerated dose was not defined. No reproducible changes were seen in DCE-MRI end points. Serial assessments of VEGF
in a cohort of patients treated at 145mgm
 2 did not show a statistically significant treatment-related change. Parallel assessments of
the impact of SU5416 on coagulation profiles in six patients showed a transient effect within the fibrinolytic pathway. Clinical
experience showed that patients who had breaks of therapy longer than a week could not have treatment reinitiated at a dose of
190mgm
 2 without unacceptable toxicity. The 145mgm
 2 dose level is thus the recommended dose for future study.
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SU5416 (Z-3-[(2,4-dimethylpyrrol-5-yl)methylidenyl]-2-indoli-
none; semaxanib) has been developed as a potent inhibitor of
the receptor tyrosine kinase for vascular endothelial growth factor
receptor – Flk-1/KDR (VEGFR2) (Figure 1). This receptor pathway
plays a crucial role in the process of angiogenesis. Targeting
angiogenesis is highly attractive as a strategy to control
malignancy. Such a therapy should be less susceptible to the
development of resistance, since the target is normal endothelial
cells, and as the majority of normal tissue is not actively
developing vasculature, it should not be accompanied by the
toxicity of conventional cytotoxics.
SU5416 is also a potent competitive inhibitor of KIT (the
receptor for stem cell factor) and less potently the PDGF receptor
(indirectly involved in angiogenesis), but is not directly cytotoxic
by itself (Antonian et al, 2000; Smolich et al, 2001; Yee et al, 2002).
Recent work has also suggested that SU5416 may mediate some of
its effects through inhibition of a second VEGF receptor – Flt-1
(VEGFR1) (Itokawa et al, 2002). Preclinical xenograft models have
confirmed inhibition of tumour growth and a reduction in the
number of metastases following treatment with SU5416 (Fong et al,
1999), as well as a decrease in vascular density in treated tumours
as measured by intravital video-microscopy (Vajkoczy et al, 1999;
Vaskoczy et al, 2000).
Theoretically, an antiangiogenic treatment may prove initially
cytostatic rather than cytoreductive. As such, chronic therapy may
be required, issues of toxicity and compliance become increasingly
important and it would be clinically desirable if one could identify
responding patients at the earliest juncture. Thus ideally in
preclinical investigations, but certainly in the Phase I clinical
setting, it is critical to validate noninvasive pharmacodynamic
tools that indicate a dose-dependent biological effect.
In this Phase I trial, the primary objective was to assess the
safety and tolerability of SU5416 when administered twice weekly
via intravenous infusion. Secondary objectives were to quantify
effects on tumour vascular permeability using low-molecular
weight dynamic contrast-enhanced magnetic resonance imaging
(DCE-MRI), to assess the pharmacokinetics (PK) of SU5416 and to
correlate PK with DCE-MRI. This use of imaging to assess vascular
permeability was designed to investigate SU5416 pharmacody-
namics in humans for the first time in a structured dose escalation
manner, in an effort to determine an effective dose for further
development. It is thus unique among parallel Phase I studies with
this compound hitherto reported (Rosen et al, 1999; Stopeck et al,
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s2002). In addition, effects on coagulation and VEGF levels were
explored and any evidence of antitumour activity was reported.
PATIENTS AND METHODS
Clinical protocol
The study protocol was approved by the Research Ethics
Committee of the Royal Marsden NHS Trust. Written informed
consent was obtained from all participants. All patients had
treatment refractory solid tumours and were required to have at
least one tumour deposit suitable for DCE-MRI evaluation. A
suitable lesion had to be X2cm in size and in an anatomical
position not subject to significant respiratory excursion. Eligible
patients had not received treatment with any other anticancer
therapy for 4 weeks prior to treatment with SU5416. Patients were
required to have adequate baseline haematological reserves
(absolute neutrophil count X1.5 10
9l
 1, platelet count
X100 10
9l
 1, haemoglobin X9.0gdl
 1). In addition, all patients
were required to have adequate systemic organ function (i.e. serum
transaminases o2.5 times the upper limit of normal; total
bilirubin o34.2mmoll
 1; and serum creatinine o160mmoll
 1 or
creatinine clearance X50mlmin
 1). Exclusion criteria included
patients with a known history of allergy to radiologic contrast
agents or to Cremophor
s; a Karnovsky performance status of
o60%; a history of myocardial infarction, severe or unstable
angina within 6 months of the study; diabetes mellitus with clinical
evidence of severe peripheral vascular disease or ulceration; a
medical condition or device implant that would interfere with or
prevent MRI scans; or a serious concomitant medical condition
that could interfere with the participation in the study or
interpretation of study results.
The starting dose of SU5416 for the study was 48mgm
 2. This
dose was chosen in the light of available clinical experience in a
concomitant Phase I trial underway in Los Angeles. Sequential
cohorts of three patients were recruited. Dose escalation steps of
33% were planned. The National Cancer Institute Common
Toxicity Criteria V1 was used to grade toxicity. Dose-limiting
toxicity (DLT) was defined as the occurrence of: Grade III or
greater toxicity excluding nausea/vomiting and haematologic
toxicity; or Grade IV haematologic toxicity; or Grade IV nausea
and vomiting refractory to antiemetic therapy. When DLT was
observed in one patient in a cohort, the dose level was expanded to
six patients. The maximum-tolerated dose in this study was
defined as the dose level below which DLT occurred in X2 of the
six patients treated in the cohort. Intrapatient dose escalation was
permitted.
SU5416 was administered twice weekly via intravenous infusion
at a fixed rate of 200mlh
 1. All patients received intravenous
chlorpheniramine (10mg), dexamethasone (10mg) and ranitidine
(50mg) as premedication 1h before treatment, to minimise
hypersensitivity reactions attributable to the excipient Cremo-
phor
s.
Patients were monitored for at least 1h after treatment. Samples
for haematology, coagulation studies, biochemistry and urine
analysis were taken on day 15 and four weekly thereafter. Full
tumour re-evaluation was performed every 6 weeks using WHO
response criteria. Patients were allowed to continue to receive
therapy with SU5416 indefinitely in the absence of unacceptable
toxicity or evidence of tumour progression.
Study drug – SU5416
SU5416 (SUGEN Inc., South San Francisco, CA, USA) was supplied
as a yellow-orange liquid formulation in 30ml vials each contain-
ing 112.5mg of drug in 25ml of vehicle for a final concentration of
4.5mgml
 1. Vehicle constituents in the formulation included:
polyethylene glycol 400; polyoxyl 35 castor oil (Cremophor
s); and
benzyl alcohol and dehydrated alcohol. The vials were stored at
room temperature (22–281C) and were protected from light. Prior
to administration, SU5416 was diluted 1:3 with 0.45% sodium
chloride and injected into non-PVC intravenous infusion bags.
Treatment infusions were administered through non-PVC, non-
DEHP intravenous tubing and a 0.2mm in-line filter (not made
from cellulose acetate).
PK evaluation
Plasma samples for the determination of SU5416 and its
metabolites were drawn on day 4 and day 25. Samples were taken
prior to treatment infusion, 15min into the infusion, at completion
of the infusion and then at 5, 10, 20, 30, 45, 60, 120 and 240min
following the infusion. Blood samples were drawn from the
contralateral arm or distant from the venous access device used for
the administration of SU5416. At the designated times, 4.0ml of
blood were collected into a lithium heparin tube, gently inverted
and placed on ice to maintain the sample at 2–81C. All samples
were immediately centrifuged at 6000r.p.m. at 41C for 10min, the
supernatant divided between two 1.5ml Nalgene cryovials and
snap frozen in liquid nitrogen. Separated plasma samples were
subsequently stored at  701C until analysis.
Pharmacokinetic analysis was performed using a fully validated
HPLC UV method (Stopeck et al, 2002). Plasma samples, standards
(25–2000ngml
 1) and quality controls spiked with internal
standards were extracted with acetonitrile. Following centrifuga-
tion, drying and reconstitution in 200ml mobile phase, 20ml were
analysed by HPLC UV. Chromatography was carried out using a
C18 analytical column, with a gradient mobile phase containing
acetonitrile and 10mM ammonium formate at pH 2.6. The flow rate
was 0.8mlmin
 1 and the run-time 21min. Detection was via UV
absorption at a wavelength of 440nm. The accuracy of the assay,
reflected in relative error of measured concentration to theoretical
(prepared) concentrations, was between 0.9 and 5.6% for all
quality control samples.
Pharmacokinetic parameters were evaluated using WinNonLin
Software
s. A comprehensive PK profile of SU5416 and its
metabolites SU6595 and SU9838 (Cmax, Tmax, T1/2a, T1/2 and Kabs)
was determined for each patient.
Pharmacodynamic evaluations – VEGF
Assessment of VEGF levels was incorporated by amendment from
the 145mgm
 2 dose level.
Samples for the measurement of VEGF levels were drawn at
baseline, on day 1 at 2, 4 and 24h, after the treatment infusion. At
each time point, blood was drawn into a plain tube (serum), a
sodium citrate tube (platelet-rich plasma) and a CTAD (platelet-
stabilised plasma) tube. CTAD tubes (Becton-Dickinson Vacutainer
N
H
N
H
O
Figure 1 SU5416 chemical structure, 3-[(2,4-dimethylpyrrol-5-yl)methy-
lideneindolin-2-one.
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sSystems, Europe) contain four anticoagulants: sodium citrate,
theophylline, adenosine and dipyridamole, and are designed to
minimise any platelet activation that may occur as a result of blood
collection.
Vascular endothelial growth factor was measured by enzyme-
linked immunosorbent assay (ELISA) using the commercially
available Quantikine Kit (R&D Systems, Europe). This analysis was
conducted at The Institute of Cancer Research, Sutton, UK.
Pharmacodynamic evaluation – DCE-MRI
All patients were asked to have a baseline DCE-MRI examination
within the 7 days prior to receiving the study compound under
study conditions as described above. Follow-up scans were
performed on day 1 and then after 4 weeks of therapy. After the
first three patients’ examination, the protocol was amended to day
1, 2 weeks, 6 weeks and 6 weekly thereafter if the patient remained
on study. All examinations were performed on a 1.5T MRI system
(Vision, Siemens Medical Systems, Erlangen, Germany) approxi-
mately 4h after the commencement of the treatment infusion.
The image collection protocol comprised routine orthogonal
T1- and T2-weighted images taken through the previously identified
target lesion, to allow localisation and bi-dimensional tumour
measurement. The dynamic imaging used a five-slice saturation
recovery turbo fast low-angle shot sequence (SRTF) taken through
the centre of the target lesion. Proton density-weighted images
were acquired, followed by a series of T1-weighted images
employing the same gain and image scaling factors. The sequential
T1-weighted images were acquired every 9s for 6.3min (42 time
points).
Gadopentetate dimeglumine (Magnevist Schering Health Care
Limited, Burgess Hill, Sussex, UK) was injected intravenously
using a mechanical power injector, through a peripherally placed
cannula. This contrast was administered as a bolus after the third
baseline data point was acquired at a dose of 0.1mmolkg
 1 body
weight. The use of the mechanical power injector allowed the
contrast to be delivered within 10s. The contrast injection was
followed by a 20ml flush of normal saline.
Using the resultant scanned images, two trained observers (AP,
CH) blinded to the clinical outcome of the patients evaluated the
patterns of enhancement within a designated region of interest.
Contrast medium kinetic parameters were then derived for each
pixel using MR Imaging Workbench software
s. Quantitative and
semiquantitative statistical analysis was then performed on these
parameters using StatsDirect software (Research Solutions,
Cambridge, UK).
Expanded coagulation series
During the dose escalation stage of the protocol, a standard series
of coagulation parameters (APPT, INR and fibrinogen) was
explored at baseline prior to therapy and every 2 weeks thereafter.
In the dose expansion phase of the protocol, in response to the
clinical occurrence of two separate venous thrombotic episodes in
study patients, an expanded coagulation series was performed.
Samples were taken on cycle 1, day 1 prior to, then at 4 and 24h
following the infusion of SU5416 and on cycle 1, day 4 and day 25
prior to, then 4h after the SU5416 injection.
At each time point, blood was collected in citrated and EDTA
tubes (Becton-Dickinson Vacutainer Systems, Europe). The
samples from the citrated tubes were immediately centrifuged (at
41C for 10min at 3000r.p.m.) supernatants pooled into inert
plastic, centrifuged again (at 41C, 10min at 3000r.p.m.) and the
resultant sample stored in inert plastic tubes at  701C until
analysis. The sample taken into EDTA was centrifuged (at 41C, for
10min at 3000r.p.m.), the supernatant decanted into inert plastic
tubes and again stored at  701C until analysis.
RESULTS
Patient characteristics and dose escalation
In all, 27 patients received treatment with SU5416 on this study.
Descriptive details of the patients are shown in Table 1.
Sequential cohorts of three patients were treated at 48, 65, 85,
110, and then 145mgm
 2. In this dose escalation phase, a total of
24.5 cycles of SU5416 were administered (median per patient, 1.5;
range 0.5–4). During the conduct of this trial, investigators in a
parallel Phase I trial of SU5416 on the same schedule at The
University of California, Los Angeles, USA reported DLT
(projectile vomiting and severe headache) at 190mgm
 2 (Rosen
et al, 1999). Pharmacokinetic studies in our trial (see below) had
identified induction in the metabolism of SU5416 occurring within
the first weeks of therapy. Therefore, it was decided to conclude
the current study with a final dose expansion cohort of patients
receiving 145mgm
 2 twice weekly for four doses, escalating the
dose to 190mgm
 2 if well tolerated for subsequent therapy. In all,
12 patients were recruited to this expansion phase of the trial
receiving in total 29.5 cycles of therapy (median 2.5; range 0.5–5).
Pharmacokinetics
The PK results for the 25 patients evaluable are presented in
Table 2. SU5416 was well distributed with a large volume of
distribution (Vd 39–215L). Plasma clearance was rapid (CL 46–
215lh
 1), but with large interpatient variability for which there is
no obvious explanation. SU5416 displayed linear kinetics over the
dose range 48–145mgm
 2 (Figure 2) at initial assessment and
also on day 25. However, the mean AUC at 190mgm
 2 in those
patients escalated from 145mgm
 2 to the higher dose after 2
weeks did not differ significantly from that observed at 145mgm
 2
(36117183 vs 37237930mgl
 1h
 1). A similar plateau is observed
in mean peak concentration. (Table 2) In five of the nine patients
who were dosed at the same level on both day 4 and day 25, there
was an average increase in drug clearance of 22%.
SU6595 (the carboxyl derivative) was the predominant metabo-
lite representing on average 78% of the parent, while SU9838 (the
hydroxyl derivative) comprised only 5.2% of the total. Both
metabolites behaved as the parent drug with a large volume of
distribution and rapid clearance. Neither metabolite shows
inhibitory activity for any of the receptor tyrosine kinases
inhibited by the parent compound (Mendel et al, 2000). The
increase in clearance observed for the parent compound between
day 4 and day 25 was not associated with an increase in the plasma
AUC of the main metabolite, SU6595 (data not shown). There was
no correlation between toxicity and any of the PK parameters
evaluated in this study.
Table 1 Patient characteristics
Patient characteristics
Age Median 48 years
Range 18–74 years
Gender 13 males and 14 females
Tumour types
Soft-tissue sarcoma 10
Ovary/cervix/endometrium 4
Melanoma 3
Renal 2
Head and neck 2
Other (one each) Osteosarcoma, adrenocortical, small cell,
transitional cell, gastro/oesophageal junction,
Ca unknown primary
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With the exception of hypersensitivity, the intravenous infusion
of SU5416 was well tolerated. Despite premedication, Grade II
hypersensitivity reactions affected 11 patients and occurred
independent of the dose of SU5416. All patients were able to
continue to receive therapy with increased corticosteroid cover.
Tachyphylaxis did occur and the steroid dose was able to be
gradually reduced in each patient affected.
Moderate thrombophlebitis was common when peripheral
access was used. For those who continued with treatment for
multiple cycles, central line access was recommended. Other acute
toxicity included headache, fatigue, nausea and occasional
vomiting. Such symptoms were mild, dose related and most
commonly observed in the dose expansion cohort. Of interest,
Table 2 Pharmacokinetic results
Patient Dose (mgm
 2) Cycle Cmax (lgl
 1) AUClast (h
algl
 1) T1/2kz (h) CL (observed) (lh
 1) Vz (observed) (l)
1 48 1inj2 1737 463 0.54 181 142
2 48 1inj2 2724 848 0.51 94 69
1inj8 2059 630 0.61 125 109
2inj8 1629 498 0.57 158 131
3 48 1inj2 2253 1143 0.61 83 72
1inj8 1289 816 0.42 115 69
4 65 1inj3 2074 566 0.20 190 55
5 65 1inj2 4371 1498 0.45 64 41
1inj8 4105 1312 0.73 74 78
7 65 1inj2 2968 2510 0.82 74 88
1inj8 2914 2068 0.65 89 84
8 85 1inj2 2335 1809 0.39 79 45
1inj8 3672 2375 0.60 60 52
2inj8 2804 1619 0.74 88 94
9 85 1inj2 1624 1151 0.71 133 136
10 85 1inj2 2057 2094 0.71 102 104
1inj8 1354 1250 2.05 151 447
11 110 1inj2 3507 4016 0.62 46 41
12 110 1inj2 2750 2345 0.69 70 70
13 110 1inj2 3237 3842 0.55 83 66
1inj8 3578 3796 0.62 84 75
14 145 1inj2 4851 4946 0.87 55 69
1inj8 3922 4428 0.57 62 51
15 145 1inj2 2869 3471 0.89 92 119
16 145 1inj2 1217 2021 0.71 150 153
1inj8 2080 2349 0.67 169 164
2inj8 1342 1779 0.72 224 233
17 145-190 1inj2 4159 3389 0.68 64 63
1inj8 3370 4467 0.62 63 57
18 145-190 1inj2 2474 1928 0.50 96 70
1inj8 2274 2390 0.50 103 74
3inj2 6517 7173 0.75 44 48
19 145-190 1inj2 2961 3683 0.79 66 75
2inj1 4002 6451 0.77 49 54
20 145-190 1inj2 2774 3397 0.66 89 85
1inj8 2066 2611 0.81 151 176
2inj8 3341 5044 0.72 79 82
21 145-190 1inj2 2894 2621 1.36 100 196
1inj8 2161 2178 2.38 142 488
22 145-190 1inj2 2795 2870 0.67 101 97
23 145-190 1inj2 3202 2465 1.15 72 119
24 145-190 1inj2 1177 1267 0.38 215 118
1inj8 493 816 0.42 352 214
25 145-190 1inj2 4508 4094 0.49 55 39
1inj8 4283 5360 0.58 56 46
27 145-190 1inj2 2625 1578 0.69 106 106
Cmax¼maximum concentration; Tmax¼time of maximum observed concentration, AUClast¼area under the curve from time of dosing to the last measurable concentration;
AUCinf¼area under the curve from the time of dosing to infinity; t1/2lz¼terminal half-life ln2/lz, where lz is the first-order rate constant associated with the terminal log-linear
portion of the curve; MRTlast¼mean residence time from the time of dosing to the last measurable concentration; Vz¼volume of distribution based on the terminal phase dose/
lz*AUCinf;C L¼total body clearance.
aPatient 6 and 26 – not evaluable for PK, samples not taken.
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Figure 2 Pharmacokinetics: AUC vs dose demonstrating linearity and
the induction of metabolism between week 1 and week 4.
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sthree patients in this cohort also reported pain or burning
discomfort in tumour-related sites shortly after treatment infu-
sions. Such symptoms were short lived and did not require
intervention. Vital signs were monitored prior to and after
treatment for the duration of the schedule. No predictable or
persistent changes were observed. Two patients who received
therapy for 6 weeks or more developed dysphonia. This did prove
to be reversible over several months.
One patient (dose level 145-190mgm
 2, on study 20 weeks)
developed recurrent Grade II anaemia that was felt to be related to
SU5416. A further patient (dose level 145-190mgm
 2) developed
a mild (Grade I) elevation in hepatic transaminases, which may
have been due to study therapy, but this patient, with ovarian
cancer, was known to have a disease plaque adjacent to the porta
hepatis. These were, however, the only haematological and
biochemical drug-related adverse events.
Venous thrombotic events occurred in two patients while they
were receiving treatment with SU5416 (thrombosis of the inferior
vena cava and a pulmonary embolism). Both patients had serious
concomitant risk factors for such medical problems, and these
events occurred at differing dose levels, but it is not possible to
exclude an association with SU5416. The criteria for maximum-
tolerated dose were not met. Of the remaining 26 patients who
received SU5416 on this study, five were receiving low-dose
warfarin for prophylaxis of central venous access lines and one
patient was receiving therapeutic warfarin for hereditary coagulo-
pathy.
Coagulation
No change in INR, APTT or fibrinogen was observed. In all six
patients evaluated using the expanded panel, a consistent acute
increase in plasminogen activator inhibitor (PAI-1) levels was
observed with recovery at 24h (median change 37.3IU; range
14.23–61–27). A parallel reduction in plasmin–anti-plasmin
complexes (median change 12.7mgl
 1; range 0–36) was also seen.
There were no consistent changes in the coagulability parameters:
anti-thrombin III, protein C (act), protein S (free), activated
protein C resistance, dRVVT, endogenous thrombin (generation)
potential (extrinsic and intrinsic), prothrombin fragments 1 and 2
and thrombin–anti-thrombin complexes. No change was seen in
the endothelial cell haemostatic properties: thrombomodulin or
Von Willebrand factor (activated and agglutinated).
Tumour response
Two patients were not evaluable for response because major
intercurrent illness, unrelated to therapy with SU5416 occurring
after o2 weeks of therapy, precluded disease assessment
(pneumonia, bowel obstruction). In all, 12 patients were con-
sidered to have stable disease at 6 weeks and went on to receive
further treatment. Of these, three patients remained on therapy for
more than 12 weeks (disease types: haemangioendothelioma,
ovarian and adrenocortical carcinoma). The patient with advanced
adrenocortical carcinoma was shown to have a differential
response with reduction in size of a major metastatic lesion in
the retroperitoneum, stable disease in other nodal sites but
progressive disease in the liver. In light of this observation, he
went on to receive a further 6 weeks of therapy; however, with
further evidence of tumour progression in the liver lesions, he was
withdrawn from the study. Progressive disease was the best
response in 14 patients. One of these, a 53-year-old woman with
advanced head and neck carcinoma, was deemed to have
progressive disease having developed necrosis of the nasal area.
It is possible that this represented a tumour response, but
palliation was clearly not being achieved. On cessation of therapy,
there was an improvement in the degree of tumour-related
erythema and pain.
Pharmacodynamics
VEGF VEGF profiles are available for nine patients in the final
cohort. As expected, serum VEGF levels were universally higher
than those obtained from Plasmacitrated or platelet-stabilised
plasma (Plasmactad). A significant correlation between the
VEGF–Plasmactad levels and those in VEGF–Plasmacitrated was
found (r
2¼0.61 Po0.0001); however, there was no comparable
correlation with serum values (Figure 3).
When the percentage change in VEGF level from baseline was
assessed over time, there was a trend suggesting that the levels
dropped initially with subsequent rebound. However, the sample
size was small, the variance wide and the change did not reach
statistical significance (Figure 4).
DCE-MRI In all, 24 patients were evaluable for changes in
vascular permeability. A total of 80 MRI examinations were
performed in total: 24 patients at baseline; 24 patients on day 1 (3–
4h post-therapy); 17 patients were scanned mid-treatment (after 2
weeks of therapy) and 15 after more than 4 weeks (at a time point
adjacent to standard tumour evaluation).
At baseline, seven patients proved unassessable. Initial tumour
median transfer constant (K
trans) was 0.237min
 1 with values
ranging from 0.091 to 1.325. Median Ve was 32.5% (range 11–
45%). Pretreatment kinetic parameters did not predict for eventual
tumour response.
Nine patients were not evaluable on the first day of treatment.
One patient, with metastatic melanoma (target lesion – brain), had
a statistically significant change in K
trans, 91% increase. No
statistically significant changes in leakage space (Ve) were seen.
No dose response was seen in any parameter at this early time
point.
Of the 17 patients evaluated mid-treatment, seven were
unassessable. One patient with squamous cell carcinoma and
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sdisease in the nasopharynx receiving 110mgm
 2 showed marked
reductions in K
trans ( 51.9%) and Ve ( 48.6%). There was no
evidence of a dose response in any kinetic parameter after 2 weeks
of therapy.
The median time to the final scan was 35 days (range 28–58
days). Seven of the 15 patients scanned at this time point proved
assessable. Two patients had statistically significant increases in
leakage space (36.5 and 34.5%). The first, a patient with soft-tissue
sarcoma, treated at 48mgm
 2, was found to have progressive
disease. The second, again soft-tissue sarcoma, was treated in the
final expansion cohort, and was shown to have stable disease at
the 6-week assessment. Again there was no evidence of a dose
response in the kinetic parameters obtained.
The changes in K
trans across all dose levels and time points are
summarised graphically in Figure 5.
DISCUSSION
A maximum-tolerated dose of SU5416 when administered as a
twice weekly intravenous infusion was not identified in this study.
Utilising PK observations, we have shown that it is possible to
deliver 190mgm
 2 on a protracted basis after an introductory
phase of 2 weeks therapy at a lower dose. This dose was previously
determined to cause DLT. In the parallel phase one trial conducted
by Rosen et al (1999) using the same schedule as used here, DLTs
of projectile vomiting, headache and nausea, were reported at
190mgm
 2. In the dose expansion cohort of our current study
(145-190mgm
 2), there were patients who experienced mild
headache and emesis. Clinical experience also showed that patients
who had breaks of therapy longer than a week could not have
treatment reinitiated at a dose of 190mgm
 2 without unacceptable
toxicity. The 145mgm
 2 dose level was thus considered the
recommended dose for future study.
Acute hypersensitivity reactions attributable to the diluent
Cremophor
s were common. However, in oncology practice such
reactions are well recognised and can be easily managed. In all
patients in this study, a gradual reduction in prophylactic steroid
dose was possible and did not preclude sustained therapy.
The overall tolerability of intravenous SU5416, particularly when
central venous access was utilised, was good. Such characteristics
are important with an antiangiogenic compound such as this,
where chronicity of therapy is expected and the toxicity thresholds
are therefore necessarily set lower.
Homeostasis of coagulation in humans is achieved through a
complex balance of plasma, tissue and endothelial factors. The
process of tumoral angiogenesis mediated through the VEGF
family of growth factors will have effects on vascular permeability
and endothelial cell proliferation. Thus, we postulated that
targeting these pathways with a drug such as SU5416 might result
in physiological consequences within the coagulation pathway.
Although the sample size examined was small, a consistent finding
was the observation of an increase in PAI-1 levels in the acute
phase (2–4h after infusion) and a parallel reduction in PAP
complexes. These changes reflect a transient effect within the
fibrinolytic pathway. In those patients with additional risk factors,
modulation of PAI-1 and PAP could contribute to an excessive
hypercoagulable state and clinical thrombosis. This observation
may relate to the concomitant administration of dexamethasone
(Huang et al, 1995; Ha et al, 2002), although a relationship with
SU5416 is also possible. Other than thrombophlebitis directly
related to the infusion sites, only two thrombotic episodes, both
venous, were observed in this study. It is important to note,
however, that almost a quarter of patients received concomitant
warfarin therapy, which even at low dose may have been sufficient
to ameliorate this hypercoagulable propensity. An increased
incidence of thromboembolic events has been reported in
combination studies with SU5416 (Kuenen et al, 2002a; Cooney
et al, 2005). In affected patients, Kuenen et al (2002b) found an
increase in markers of thrombin generation and endothelial cell
activation, which occurred in a cycle-dependent manner. Discern-
ing the contribution of SU5416 alone to these findings is difficult.
Although increased numbers of thrombotic events are not a feature
of the parallel single-agent Phase I reports (Rosen et al, 1999;
Stopeck et al, 2002), this is perhaps a feature of study size.
Thrombotic events are reported in a number of the single-agent
Phase II studies in the literature to date (Heymach et al, 2004;
Peterson et al, 2004). Further exploration of this area is warranted
and prophylactic anticoagulation is recommended in all combina-
tion studies (Cooney et al, 2005).
Pharmacokinetic evaluations confirmed time-dependent induc-
tion of SU5416 metabolism. In this study, the degree of induction
(22%) was less than that seen in the parallel Phase I study (69%)
using the same schedule (Cropp et al, 1999; Rosen et al, 1999). As
the PK sampling for our current study was performed on day 4, in
contrast to day 1 in the Rosen trial, it is likely that the induction
in enzymes of metabolism occurs as early as the first dose. As
such, the change in clearance mechanisms was probably largely
complete by the time blood sampling was performed during and
after the second infusion (day 4) in our study. Interestingly, the
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Figure 5 Dose-related changes in K
trans using DCE-MRI (displaying mean
and standard deviation).
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Stopeck et al (2002) demonstrate a loss of any induction with a
treatment interval of 7 days. The mechanism for the induction in
SU5416 metabolism is not understood in detail but may relate to
the upregulation of cytochrome P450 isoenzymes (Antonian et al,
2000). The degree of interpatient variability in AUC is tolerable
given the kinetics are linear and the toxicity profile is favourable.
We believe that the variability is largely driven by interpatient
differences in handling of SU5416 as the assay has been well
validated and results are consistent across trials. As SU5416 in
humans is metabolised through liver microsomes to at least six
metabolites (Antonian et al, 2000), again the explanation for the
degree of variability is most likely explained by differences in
pharmacogenomics of cytochrome P450 enzymes, affecting the
metabolism of SU5416 and probably influenced by drug–drug
interactions. Our results show that SU5416 has a large volume of
distribution and clears rapidly. This is consistent with the
assessments in preclinical models (Antonian et al, 2000). Initial
preclinical models also demonstrated that the intracellular half-life
of SU5416 is long and levels capable of target inhibition are
maintained for 448h, with target inhibition resulting in successful
inhibition of tumour growth (Fong et al, 1999), thus a twice weekly
infusion schedule was recommended. In vivo experiments,
however, do not confirm the durability of this inhibition, further
emphasising the importance of developing accurate pharmaco-
dynamic markers in the clinical development of such compounds
(Mendel et al, 2000).
It is now generally acknowledged that serum samples are
inappropriate for the measurement of VEGF, as platelets, especially
when activated in clot formation, provide a rich source of this
growth factor (Maloney et al, 1998; Wynendaele et al, 1999;
Jelkmann, 2001). The plasma samples obtained in sodium citrate
and those in the CTAD were reproducible, correlated well and one
method is not preferred over the other. Although the results did
not reach statistical significance, a trend was suggested with an
initial drop in VEGF levels within the first 4h following infusion,
rebounding by 24h. The timing of this observation suggests it may
reflect the action of dexamethasone (Huang et al, 1995; Ha et al,
2002).
Dynamic contrast-enhanced MRI offers a unique opportunity
for noninvasive functional assessment achievable on most
clinically available MR systems. In a similar study with the VEGFR2
and VEGFR1 inhibitor PTK787/ZK22584 (Thomas et al, 2001;
Thomas et al, 2002), a correlation was demonstrated between a
reduction in Ki (equivalent to K
trans) and both dose and plasma
levels of the study compound. In this study, the tumours studied
were liver metastases from colorectal cancer and patients at all
dose levels administered were evaluated using DCE-MRI.
New blood vessels in tumours are structurally abnormal; leaky,
with fragmented supportive structures (pericytes and basement
membranes). A successful antiangiogenic therapy would therefore
result in stabilisation of the vasculature, a reduction in perme-
ability, levels of interstitial fluid hypertension and thus the size
of the leakage space (Fox et al, 2001; Jain, 2005). Through PK
modelling of the behaviour of a low-molecular weight contrast
agent, DCE-MRI allows measurement of these parameters:
permeability – K
trans; leakage space – Ve (Galbraith et al, 2002;
Choyke et al, 2003). No dose–response changes were seen in K
trans
or Ve at any of the time points assessed in our trial with SU5416.
A failure to demonstrate a consistent change may reflect a number
of issues. Firstly, and most likely, it may be that SU5416 is
insufficiently potent enough to cause changes in vascular
permeability of sufficient magnitude to be seen with this tool.
Secondly, the sample size was small and as now published the 95%
confidence interval for a meaningful change in K
trans in a single
patient tumour is a change of  48 to þ83%, and for Ve 724%
(Galbraith et al, 2002). It is a limitation of our study that the design
did not include internal reproducibility or repeatability data for
the study population. Thus, our ability to determine meaningful
differences in cohorts of this size is curtailed. Thirdly, it is known
that Flk-1-KDR-mediated VEGF activity is unevenly distributed
within tumour vasculature (Holash et al, 1999; Nakopoulou et al,
2002). The ‘regions of interest’ chosen for evaluation in these
patients may not always have been representative. Finally, the
nature of the patient population in this Phase I study may have
influenced the pharmacodynamic results as patients with advanced
disease may have more mature vasculature that is functionally and
biologically less sensitive to antiangiogenic therapy. As shown by
Thomas et al (2001), a homogeneous population with progressive
or recently emergent tumours may provide a better opportunity
for demonstrating pharmacodynamic relationships than the
tumours investigated in our study.
The evidence of antitumour activity is anecdotal. One patient
with progressive haemangioendothelioma remained on study for 6
months with stable disease and only withdrew because personal
circumstances precluded her remaining in the United Kingdom. A
second patient, with squamous cell carcinoma of the nasopharynx
developed necrosis of her tumour while receiving treatment. On
cessation of therapy, there was clinical improvement in local
induration and pain. Particularly when viewed in the context of the
marked decrease in vascular permeability observed in this patient
on MR, this may represent evidence of biological activity with
SU5416. In early clinical studies conducted in patients with
tumours characterised by particularly strong signalling through
the VEGF2 receptor, for example, Kaposi’s sarcoma and haeman-
gioblastoma associated with von Hippel–Lindau syndrome,
SU5416 has demonstrated encouraging activity (Miles et al, 2000;
Aiello et al, 2002; Jennens et al, 2004). In larger Phase II studies
conducted in solid tumours, the response rates have been
disappointing (Heymach et al, 2004; Peterson et al, 2004; Stadler
et al, 2004). It seems likely that although the dose level
recommended by the Phase I studies achieves systemic levels that
in preclinical modelling produced target and tumour growth
inhibition (Fong et al, 1999; Mendel et al, 2000), it does so only
transiently, and that successful therapeutic angiogenesis inhibition
requires continuously above the threshold for inhibition of a
critical pathway. Alternatively, the intrinsic redundancy of
signalling mechanisms associated with the angiogenic process
may convey tumour resistance to antiangiogenic compounds
acting mainly on a single target (Kanno et al, 2000; Fox et al, 2001).
Further trials using combinations of therapies in this class or
kinase inhibitors with broader target specificities are required.
A twice weekly infusion of SU5416 is safe and able to be
delivered in a protracted manner. Treatment can achieve
potentially therapeutic systemic levels of SU5416. Understanding
the PK behaviour of the drug has allowed us to develop an
intrapatient dose escalation schedule (145mgm
 2 twice weekly for
2 weeks, increasing to 190mgm
 2 if well tolerated), which
overcomes the lowering of plasma concentration resultant from
induction of drug metabolism. This trial failed to demonstrate a
pharmacodynamic effect using DCE-MRI, but does illustrate some
of the challenges inherent in conducting such studies. Incorpora-
tion of DCE-MRI in further studies with antiangiogenic therapy is
important for the validation of this tool, but we would suggest that
such studies include an intrapatient baseline assessment of
reproducibility and cohort sizes of sufficient number to determine
meaningful differences.
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